Clinical Laboratory, DongYang People's Hospital, Dongyang, Zhejiang, China.
PLoS One. 2020 Apr 2;15(4):e0230979. doi: 10.1371/journal.pone.0230979. eCollection 2020.
Although many scholars have recently studied the relationships between the pretreatment neutrophil-to-lymphocyte ratio (NLR) and prognosis in patients with small cell lung cancer (SCLC), the conclusions have been inconsistent. Accordingly, in this meta-analysis, we attempted to assess the clinicopathological and prognostic value of the pretreatment NLR in SCLC. Related literature was searched using PubMed, Embase, Cochrane Library, Web of Science, Chinese Biomedical Literature, China National Knowledge Infrastructure (CNKI), and Wanfang databases. Each eligible study was extracted, and a meta-analysis was performed using hazard ratios (HRs) and 95% confidence intervals (95% CIs) to assess the prognostic value of NLR. Evaluation of the clinicopathological significance of NLR in SCLC used odds ratios (ORs) and 95% confidence intervals (95% CIs). We included a total of 20 studies with 21 outcomes (5141 patients) in this meta-analysis. The results showed that high pretreatment NLR was closely related to poorer progression free survival (PFS) and overall survival (OS) (PFS, HR = 1.55, 95% CI = 1.27-1.88, P < 0.0001; I2 = 0%; OS, HR = 1.40, 95% CI = 1.26-1.55, P < 0.00001; I2 = 64%). In addition, pretreatment NLR was significantly associated with clinical stage of SCLC (OR = 2.14, 95% CI = 1.35-3.39, P = 0.001). Our meta-analysis showed that high levels of pretreatment NLR were significantly associated with a more serious clinical stage and poorer PFS and OS in SCLC.
虽然最近有许多学者研究了小细胞肺癌（SCLC）患者治疗前中性粒细胞与淋巴细胞比值（NLR）与预后之间的关系，但结论并不一致。因此，在本荟萃分析中，我们试图评估治疗前 NLR 在 SCLC 中的临床病理和预后价值。使用 PubMed、Embase、Cochrane 图书馆、Web of Science、中国生物医学文献、中国国家知识基础设施（CNKI）和万方数据库检索相关文献。提取每个合格的研究，并使用风险比（HRs）和 95%置信区间（95% CIs）进行荟萃分析，以评估 NLR 的预后价值。使用优势比（ORs）和 95%置信区间（95% CIs）评估 NLR 在 SCLC 中的临床病理意义。我们共纳入了 20 项研究，共计 21 个结局（5141 例患者）进行了本荟萃分析。结果表明，治疗前 NLR 较高与无进展生存期（PFS）和总生存期（OS）较差密切相关（PFS，HR = 1.55，95%CI = 1.27-1.88，P < 0.0001；I2 = 0%；OS，HR = 1.40，95%CI = 1.26-1.55，P < 0.00001；I2 = 64%）。此外，治疗前 NLR 与 SCLC 的临床分期显著相关（OR = 2.14，95%CI = 1.35-3.39，P = 0.001）。本荟萃分析表明，治疗前 NLR 水平较高与 SCLC 更严重的临床分期以及更差的 PFS 和 OS 显著相关。
